COMMUNIQUÉS West-GlobeNewswire

Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine
09/07/2026
Tris Pharma’s Wholly-Owned Subsidiary is Advancing the Development of Cebranopadol as it Prepares for New Drug Application (NDA) Submission Later This Year MONMOUTH JUNCTION, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- [...]
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
09/07/2026
New agreement is a significant commercial milestone and the Company’s first with its contract research organization partner Agreement expands NetraMark’s portfolio of AI-driven projects in central nervous system (CNS) [...]
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
09/07/2026
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Amplia Announces Publication of New FAK Inhibitor Patent Application
09/07/2026
HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by Amplia Application expands Amplia’s intellectual property portfolio supporting its FAK inhibitor program If granted, [...]
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
09/07/2026
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with [...]
Stereotaxis Completes Acquisition of Robocath
09/07/2026
ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has [...]
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
09/07/2026
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility [...]
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
09/07/2026
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin [...]
What Clinicians Ask About Cartilage Regeneration Supplements: Answering the Clinical Questions Around Cartigenix HP®
09/07/2026
Three published human studies covering more than 1,700 participants provide peer-reviewed answers to the clinical questions most frequently raised about cartilage regeneration supplementation*† SCOTTSDALE, AZ, July 09, [...]
Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 44th Annual Meeting July 15 - 18
09/07/2026
CAMBRIDGE, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that data from [...]
TOMI Reports 124% Increase in Preliminary Second Quarter Revenue; Preliminary Six Months Revenue Combined with Open Orders Surpass Full Year 2025 Revenue
09/07/2026
FREDERICK, Md., July 09, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reported robust preliminary second-quarter 2026 [...]
VisCardia Implants First U.S. Patient in RECOVER-HF Pivotal Trial
09/07/2026
Milestone in pivotal IDE evaluation of VisONE™ Synchronized Diaphragmatic Stimulation Therapy for symptomatic heart failure with reduced ejection fraction; FDA Breakthrough Device Designation PORTLAND, Ore., July 09, [...]
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
09/07/2026
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing First-Ever [...]
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
09/07/2026
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U.S. naloxone market totals ~$144 million in annual sales and ~9.8 [...]
Heald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Users
09/07/2026
Consumers purchasing Dexcom Stelo or Abbott Lingo through Heald now receive complimentary access to AI-powered glucose insights ALPHARETTA, Ga., July 09, 2026 (GLOBE NEWSWIRE) -- Heald, a digital metabolic health [...]
Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
09/07/2026
ORANGE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its second quarter 2026 financial results on Thursday, July 30, 2026, after market close. Following the release, [...]
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
09/07/2026
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus ® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to [...]
UREVO Wins Red Dot Award 2026 for AI-Powered Wireless Recovery Boots, Recognized for Real-Time, AI-Adaptive Recovery
09/07/2026
ESSEN, July 09, 2026 (GLOBE NEWSWIRE) -- Smart wellness innovator UREVO has been named a winner of the Red Dot Award: Product Design 2026 in the Innovative Design category for its AI-Powered Wireless Recovery Boots . [...]
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
09/07/2026
Proprietary dual-vector platform delivers full-length ABCA4, enabled by Atsena's laterally spreading AAV.SPR capsid for delivery to the central retina without foveal detachment ATSN-401 advancing in IND-enabling studies [...]

Pages